Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.64 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 1/20 | 0.55 |
| ▸ | PRKAB2 | O43741 | 3/20 | 0.54 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.54 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.54 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.54 |
| ▸ | PRKAG3 | Q9UGI9 | 3/20 | 0.54 |
| ▸ | PRKAG2 | Q9UGJ0 | 3/20 | 0.54 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13148292 | 0.88 | KMT2A (0.56) | HPGDSTRPV1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL13148263 | 0.85 | EPHX2 (0.60) | TRPV1EPHX2 | |
| SCHEMBL10253402 | 0.75 | CNR2 (0.88) | HPGDSCNR1CNR2PRKAB2PRKAG1 | |
| SCHEMBL14306236 | 0.75 | MAPT (0.69) | HPGDSTRPV1CNR1CNR2PRKAB2 | |
| SCHEMBL4559682 | 0.75 | MAPT (0.73) | HPGDSTRPV1CNR1CNR2PRKAB2 | |
| SCHEMBL10253411 | 0.75 | CNR2 (0.78) | HPGDSTRPV1CNR1CNR2PRKAB2 | |
| SCHEMBL15134839 | 0.74 | EPHX2 (0.69) | HPGDSTRPV1CNR1CNR2PRKAB2 | |
| SCHEMBL6153200 | 0.74 | KMT2A (0.69) | HPGDSTRPV1CNR1CNR2EPHX2 | |
| SCHEMBL3075269 | 0.74 | GNE (0.55) | LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL10253415 | 0.74 | CNR2 (0.80) | HPGDSCNR1CNR2PRKAB2PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2527340-B1 | PIPERAZINE COMPOUND HAVING A PGDS INHIBITORY EFFECT | TAIHO PHARMACEUTICAL CO LTD (JP) | 2016-08-17 | — | — | EP | disclosed |
| EP-2407466-B1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | TAIHO PHARMACEUTICAL CO LTD (JP) | 2016-01-13 | — | — | EP | disclosed |
| US-9062035-B2 | Piperazine compound capable of inhibiting prostaglandin D synthase | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-8865714-B2 | Piperazine compound capable of inhibiting prostaglandin D synthase | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-10-21 | — | — | US | disclosed |
| US-8765750-B2 | Piperazine compound having a PGDS inhibitory effect | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20140128394-A1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-05-08 | — | — | US | disclosed |
| US-20120309760-A1 | PIPERAZINE COMPOUND HAVING A PGDS INHIBITORY EFFECT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| EP-2407466-A1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | Taiho Pharmaceutical Co., Ltd. (JP) | 2012-01-18 | — | — | EP | disclosed |
| US-20110319413-A1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | HPGDS, PTGDR, PTGIS | HPGDS 1/4885TRPV1 137/4885CNR1 86/4885 |
| US-20140128394-A1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | PTGDR, PTGS1, PTGDR2 | HPGDS 9/4885TRPV1 317/4885CNR1 26/4885 |
| US-20120309760-A1 | PIPERAZINE COMPOUND HAVING A PGDS INHIBITORY EFFECT | GRIK5, GRK5, KCNJ5 | HPGDS 14/4885TRPV1 341/4885CNR1 167/4885 |
| US-20110319413-A1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | PTGS1, PTGDR, PTGIS | HPGDS 10/4885TRPV1 363/4885CNR1 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.